Abivax Shares Signal a Sustained Reversal

Abivax shares break out as UBS increases stake to 5.08% and the company nears key Phase 3 data readouts for its ulcerative colitis drug, Obefazimod.

Investors are witnessing a notable resurgence in Abivax shares as the company approaches the release of its 2025 annual report. After being confined to a narrow trading range for weeks, the stock has broken free, fueled by a significant technical shift and a major institutional investment. This activity suggests the market is anticipating upcoming catalysts from the firm's clinical development pipeline.

Institutional Confidence and Technical Momentum

A key driver behind the recent movement is a substantial position increase by Swiss banking giant UBS. The institution has raised its stake in the biotechnology specialist to 5.08%, crossing a regulatory disclosure threshold by accumulating nearly four million shares. This move is widely interpreted as a vote of confidence in the company's strategic direction.

From a chart perspective, the equity has decisively broken above the €102.18 level, surpassing its 50-day moving average. This technical breakout concludes a prolonged consolidation phase that saw the price dip to €94 in early March. With a weekly gain exceeding ten percent and the stock currently trading around €109.60, the technical outlook has markedly improved.

Clinical Milestones Drive Long-Term Outlook

While short-term price action is influenced by technical factors, the long-term trajectory for Abivax remains intrinsically linked to its lead drug candidate, Obefazimod. The therapeutic is currently undergoing Phase 3 trials for the treatment of ulcerative colitis. The progress of this and other clinical programs is the fundamental focus for stakeholders.

Key upcoming dates for investors include:
* March 23, 2026: Publication of the 2025 annual results.
* End of Q2 2026: Data readout from the Phase 3 maintenance study (ABTECT-UC).
* End of Q4 2026: Results from the Phase 2b induction study (ENHANCE-CD).

The immediate test will be whether the 2025 financial figures, due next Monday, can reinforce the current recovery. This report is also expected to provide an update on the company's financial runway for its ongoing clinical trials. Market observers suggest that if the share price maintains stability above the €102 threshold, the foundation for a continued positive trend will be firmly established.